Clinical Trial

Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

Study acronym: LB-LR1109

Recruiting Phase 1

Summary

This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose (RP2D) and to evaluate safety, tolerability, preliminary efficacy, pharmacokinetics, immunogenicity, pharmacodynamics of LB-LR1109 as monotherapy in participants with advanced and/or metastatic non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC), urothelial carcinoma, or malignant melanoma and no available standard of care treatment options, and as combination therapy with atezolizumab in participants with advanced and/or metastatic NSCLC.

Protocol Amendment History 3 amendments

This ClinicalTrials.gov record has been amended 3 times since 2024-03-22; most recent amendment 2025-11-19.

Status change: Not Yet Recruiting → Recruiting 2024-09-03

Trial Details

NCT Number	NCT06332755
Lead Sponsor	LG Chem
Conditions	Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC), Renal Cell Carcinoma(RCC), Urothelial Carcinoma, Malignant Melanoma
Enrollment	76 participants
Start Date	2024-06-05
Primary Completion	2027-11 (estimated)
Study Completion	2028-03 (estimated)
Updated on ClinicalTrials.gov	2025-11-24